Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Investor Presentation (November 2021)
26 slides from Radiopharm Theranostics's investor presentation, Nov 29, 2021
Slide 1: Investor Presentation
For personal use only INVESTOR PRESENTATION NOVEMBER 29th, 2021
Slide 2: Disclaimer
DISCLAIMER For personal use only 1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Lim
Slide 3: What Are Radiopharmaceuticals?
WHAT ARE RADIOPHARMACEUTICALS? For personal use only Diagnostic Therapeutic Radiopharmaceutical Radiopharmaceuticals Process involves attaching a radioactive isotope to a deliver radioactive isotopes to targeting agent such as a small molecule or antibody the tumour cells • Peptides or mAbs specific
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS World-class management team comprising For personal use only Highly prospective portfolio comprising C-suite executive team recruited from clinical & pre-clinical stage the most prestigious radiopharmaceuticals radiopharmaceutical assets for both companies & universities global
Slide 5: Four Distinct & Well Differentiated Platforms
FOUR DISTINCT & WELL DIFFERENTIATED PLATFORMS For personal use only BALANCED PORTFOLIO OF SMALL MOLECULES, PEPTIDES AND MONOCLONAL ANTIBODIES, WITH DIAGNOSTIC & THERAPEUTIC POTENTIAL Pivalate Nano-mAbs Avb6 Integrin PSA-mAb Phase 1 & Phase 2 | N= 49 Phase 1 | N=74 Phase 1 | N=10 Pre-clinical • Phase
Slide 6: 18F-Pivalate
18F-Pivalate PHASE 1 & PHASE 2 N=49 Pivalate Phase 1 & Phase 2 | N= 49 For personal use only RPT 18F-FPIA radiotracer is the invention of Based on a short chain carbohydrate which utilizes the early Professor Eric Aboagye of Imperial College steps of fatty acid oxidation and is very stable London In
Slide 7: Nano-mAbs
Nano-mAbs NANO-MABS N=74 Phase 1 | N=74 For personal use only The technology is based on single-domain camelid antibodies known as nano-mAbs derived from camels The technology is the invention of Dr Hong Hoi Ting formerly of Oxford University, GE Healthcare, and Shanghai National Technology Centre A
Slide 8: AVβ6 Integrin
AVβ6 Integrin AVβ6 INTEGRIN PHASE 1 IMAGING N=10 18F & 211At Phase 1 | N=10 Phase 1 & Phase 2 | N= 47 For personal use only AVβ6 is the invention of internationally regarded integrin expert AVβ6 offers an unparalleled performance for radiolabelling with Professor Johannes Notni, formerly at the Tech
Slide 9: PSA-mAb
PSA-mAb 2ND GEN PSA-mAb ANTIBODY PRE -CLINICAL Pre-clinical For personal use only Proprietary humanized monoclonal antibody (hu PSA), capable of targeting free human prostate kallikrein (PSA) in prostate cancer cells and internalizing payload. PSA-mAb is the discovery of Prof David Ulmert formerly o
Slide 10: RAD Clinical Development Pipeline
RAD CLINICAL DEVELOPMENT PIPELINE RAD Code Platform / Indication Pre-clinical Phase 1 Phase 2 Phase 3 For personal use only RAD101 Pivalate Brain Mets F-18 RAD102 Pivalate Glioma F-18 RAD104 Pivalate Kidney F-18 RAD105 Pivalate Solid Tumours F-18 RAD106 Pivalate Tx glioma I-131 &/or At-211 RAD201 Na
Slide 11: Executive Leadership Team
EXECUTIVE LEADERSHIP TEAM For personal use only RICCARDO PROF DAVID DR THOM PAUL CANEVARI MOZLEY TULIP HOPPER MANAGING DIRECTOR / CEO CHIEF MEDICAL OFFICER CHIEF TECHNICAL OFFICER EXECUTIVE CHAIRMAN Riccardo was most recently Chief David was most recently at Cornell Thom has spent more than 25 Paul
Slide 12: Recent IPOs in Radiopharmaceutical Space
RECENT IPOS IN RADIOPHARMACEUTICAL SPACE For personal use only NOV 2020 SEP 2019 JUN 2020 JUN 2020 $1.1B gross proceeds $250M gross proceeds $212.5M gross $144M gross proceeds proceeds AUG 2021 DEC 2020 SEP 2020 SEP 2018 A$92M gross proceeds $98.6M gross proceeds DKK273M gross $96M gross proceeds pr
Slide 13: Key Acquisitions in Radiopharma Space
KEY ACQUISITIONS IN RADIOPHARMA SPACE For personal use only JAN 2018 DEC 2018 JUN 2019 MAR 2021 US$3.9B US$2.1B US$450M + US$300M Approved Phase 3 Approved Phase 3 R AD I O P H A R M T H E R A N O S T I C S L T D Sources: 2021 Refer to notes section C O N F I D E N T I AL | 1 3
Slide 14: Investment Summary
INVESTMENT SUMMARY For personal use only Radiopharmaceuticals Radiopharm’s Over 130 patients World class management experiencing a high level portfolio is a balanced treated to date across team including CEO, CMO of investor interest and pipeline with risk seven clinical trials. & CTO from some of M
Slide 15: Contact Us
For personal use only CONTACT US Riccardo Canevari Paul Hopper CEO & MANAGING DIRECTOR Executive Chairman Radiopharm Theranostics Limited Radiopharm Theranostics Limited T +1 862 309 0293 T +61 406 671 515 E rc@radiopharmtheranostic.com E paulhopper@lifescienceportfolio.com W www.radiopharmtheranost
Slide 16: Appendix
For personal use only APPENDIX
Slide 17: Nano-mAbs
Nano-mAbs NANO-MABS PHASE 1 & PHASE 2 N=73 Phase 1 | N=74 For personal use only Platform: sdAb Application: Theranostic Initial targets are HER-2 for breast cancer, PD-L1 for Non -Small Cell Lung Cancer & TROP-2 for Triple Negative Breast Cancer A therapeutic product is made by a genetic engineered
Slide 18: Nano-mAbs: HER-2 Breast Imaging Complete
Nano-mAbs HER-2 PHASE 1 BREAST IMAGING COMPLETE N=33 Phase 1 | N=74 For personal use only Phase 1 imaging has been completed on 33 patients with Tecnetium-99m: 30 in Shanghai; 3 in Germany Non-invasive and demonstrated safety Accumulation / high uptake in target within 2 hours post injection Accepta
Slide 19: Nano-mAbs: HER-2 Breast Therapeutic Commencing
Nano-mAbs HER -2 PHASE 1 BREAST THERAPEUTIC COMMENCING Phase 1 | N=74 For personal use only Phase 1 therapeutic about to launch in late stage HER-2+ breast cancer at Aachen and Curanosticum Centres in Germany with Re-188 , and Lu-177 1st patients dosing ~September/October 2021 Can be easily adopted
Slide 20: Nano-mAbs: PD-L1 NSCLC Imaging Complete
Nano-mAbs PD-L1 PHASE 1 NSCLC IMAGING COMPLETE N=40 Phase 1 | N=74 For personal use only PD-L1 is a pan-cancer biomarker, and immuno-checkpoint blockers are becoming the most important treatment of multiple cancers Imaging technology is licensed to Lantheus for research collaborations in diagnostic
Slide 21: Nano-mAbs: PD-L1 Clear Uptake & Advantages of Imaging v. Biopsy
Nano-mAbs PD-L1 CLEAR UPTAKE & ADVANTAGES Phase 1 | N=74 O F I M A G I N G V. B I O P S Y For personal use only TC002-High PD-L1 expression within Primary tumour and Multiple Mets PD-L1 expression (DAKO 22C3) = 20% Primary NSCLC T:BP=3.09 Hilar Lymph Nodes (LEFT) T:BP=3.25 Hilar Lymph Nodes (RIGHT)
Slide 22: Nano-mAbs: TROP-2 and PTK7 Pre-clinical Candidates
Nano-mAbs NanoMabs TROP-2 AND PTK7 PRE-CLINICAL CANDIDATES Phase 1 | N=74 N=73 For personal use only TROP-2 PTK7 Target tumour-associated calcium signal Target Protein Tyrosine Kinase 7 transducer Gene TACSTD2 Gene PTK7 Cancer Sustaining proliferative signaling; Activating Cancer Activating invasion
Slide 23: AVβ6 - European Journal of Nuclear Medicine Image of the Month
AVβ6-Integrin AVβ6 - EUROPEAN JOURNAL OF NUCLEAR MEDICINE Phase 1 | N=10 AND MOLECULAR IMAGING – IMAGE OF THE MONTH For personal use only PET/CT imaging of pancreatic carcinoma AVβ6-specific peptide PET/CT image of solitary tumour in pancreatic head Pancreatic ductal carcinoma confirmed histological
Slide 24: AVβ6 Best-in-Class: Phase 1a Commenced
AVβ6-Integrin AVβ6 BEST-IN-CLASS: PHASE 1A COMMENCED Phase 1 | N=10 B I O D I S T R I B U T I O N G E N E R A L LY ( H E A LT H Y S U B J E C T C O M PA R I S O N ) For personal use only [18F]FP-R01-MG-F2 AVβ6 Integrin Unacceptable No deposition in biodistribution healthy tissues Considerably high E
Slide 25: PSA-mAb: Sustained Tumour Regression
PSA-mAb THERAPY SUSTAINED TUMOUR REGRESSION Pre-clinical A N D A S I G N I F I C A N T I N C R E A S E I N M E D I A N S U R V I VA L T I M E For personal use only Prostate mouse model While beta-emitting [90Y]hu PSA had a more immediate effect on tumour volume, treatment with [225Ac]hu PSA resulted
Slide 26: Peer Reviewed Publications
PEER REVIEWED PUBLICATIONS 2021 2021 2021 2021 2020 2020 For personal use only Eur J Nucl Med Mol Imaging. Am J Nucl Med Mol Imaging Clin Cancer Res. Nat Rev Urol. Drug Discov Today. EJNMMI Res. 2021 May;48(5):1371-1389 2021;11(3):XXX-XXX 2021 Apr 1;27(7):2050-2060 2021 Mar;18(3):131 2020 Dec;25(12)
Radiopharm Theranostics — Investor Presentation (November 2021) on 6ix